Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-cell mosaicism

Current Opinion in Genetics and Development

Volumn 16, Issue 3, 2006, Pages 317-322

  Luzzatto, Lucio ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; ECULIZUMAB; GLYCAN PHOSPHATIDYLINOSITOL; N ACETYLGLUCOSAMINYLTRANSFERASE; PHOSPHATIDYLINOSITOL; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CELL POPULATION; CLINICAL TRIAL; GENE; GENE LOCATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULAR CLONING; MOSAICISM; NATURAL KILLER CELL; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PIG A GENE; PRIORITY JOURNAL; REVIEW; SOMATIC CELL GENETICS; T LYMPHOCYTE; X CHROMOSOME; X CHROMOSOME LINKED DISORDER;

ANIMALS; AUTOIMMUNITY; CELL LINEAGE; GENETIC DISEASES, X-LINKED; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MEMBRANE PROTEINS; MOSAICISM;

EID: 33646495323     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2006.04.015     Document Type: Review

References (42)

1. Luzzatto L., and Notaro R. Paroxysmal nocturnal hemoglobinuria. In: Young N., Gerson S.L., and High K.A. (Eds). Clinical Hematology (2006), Mosby 326-339
2. Parker C., Omine M., Richards S., Nishimura J-i, Bessler M., Ware R., Hillmen P., Luzzatto L., Young N., Kinoshita T., et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 (2005) 3699-3709
3. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., and Lachmann P.J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion into lipid bilayers. Immunology 71 (1990) 1-9
4. Dacie J.V. Paroxysmal nocturnal haemoglobinuria. The Haemolytic Anaemias: Drug and Chemical Induced Haemolytic Anaemias, Paroxysmal Nocturnal Haemglobinuria, and Haemolytic Disease of the Newborn Volume 5 (1999), Churchill Livingston 139-330
5. Rosti V., Tremml G., Soares V., Pandolfi P.P., Luzzatto L., and Bessler M. Murine embryonic stem cells without PIG-A gene activity are competent for PNH-like hematopoiesis but not for clonal expansion. J Clin Invest 100 (1997) 1028-1036
6. Tremml G., Dominguez C., Rosti V., Zhang Z., Pandolfi P.P., Keller P., and Bessler M. Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. Blood 94 (1999) 2945-2954
7. Murakami Y., Kinoshita T., Maeda Y., Nakano T., Kosaka H., and Takeda J. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by model mice of paroxysmal nocturnal hemoglobinuria. Blood 94 (1999) 2963-2970
8. Keller P., Payne J.L., Tremml G., Greer P.A., Gaboli M., Pandolfi P.P., and Bessler M. FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to hematopoietic stem cells in the bone marrow. J Exp Med 194 (2001) 581-589
9. Jasinski M., Pantazopoulos P., Rother R.P., van Rooijen N., Song W.C., Molina H., and Bessler M. A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins. Blood 103 (2004) 2827-2834. In a complement-deficient mouse background, the authors show that PNH red blood cells still have a reduced lifespan, indicating that they are susceptible to a complement-independent mechanism of hemolysis.
10. Takeda J., and Kinoshita T. GPI-anchor biosynthesis. Trends Biochem Sci 20 (1995) 367-371
11. Hwa K.Y. Glycosyl phosphatidylinositol-linked glycoconjugates: structure, biosynthesis and function. Adv Exp Med Biol 491 (2001) 207-214
12. Rotoli B., and Luzzatto L. Paroxysmal nocturnal hemoglobinuria. Semin Hematol 26 (1989) 201-207
13. Araten D.J., Nafa K., Pakdeesuwan K., and Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 96 (1999) 5209-5214
14. Hu R., Mukhina G.L., Piantadosi S., Barber J.P., Jones R.J., and Brodsky R.A. PIG-A mutations in normal hematopoiesis. Blood 105 (2005) 3848-3854
15. Young N.S. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep 4 (2005) 103-109
16. Sugimori C., Chuhjo T., Feng X., Yamazaki H., Takami A., Teramura M., Mizoguchi H., Omine M., and Nakao S. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107 (2006) 1308-1314. The findings in this study confirm directly the notion that the pathogenesis of aplastic anemia and of PNH are closely related, favoring the notion that in PNH the expansion of the PNH clone is caused by negative selection against non-PNH cells.
17. Purow D.B., Howard T.A., Marcus S.J., Rosse W.F., and Ware R.E. Genetic instability and the etiology of somatic PIG-A mutations in paroxysmal nocturnal hemoglobinuria. Blood Cell Mol Dis 25 (1999) 81-91
18. Horikawa K., Kawaguchi T., Ishihara S., Nagakura S., Hidaka M., Kagimoto T., Mitsuya H., and Nakakuma H. Frequent detection of T cells with mutations of the hypoxanthine-guanine phosphoribosyl transferase gene in patients with paroxysmal nocturnal hemoglobinuria. Blood 99 (2002) 24-29
19. Chen G., Zeng W., Green S., and Young N.S. Frequent HPRT mutations in paroxysmal nocturnal haemoglobinuria reflect T cell clonal expansion, not genomic instability. Brit J Haematol 125 (2004) 383-391
20. Araten D.J., and Luzzatto L. The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria. Blood (2006) 10.1182/blood-2006-01-0256. This study proves that PIG-A mutations in PNH patients are not caused by an intrinsic increase in the rate of mutation, thus supporting the notion that somatic cell selection is crucial to the pathogenesis of PNH.
21. Young N.S., and Maciejewski J. The pathophysiology of aplastic anemia. New Engl J Med 336 (1997) 1365-1372
22. Feng X., Chuhjo T., Sugimori C., Kotani T., Lu X., Takami A., Takamatsu H., Yamazaki H., and Nakao S. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 104 (2004) 2425-2431
23. Karadimitris A., Manavalan J.S., Thaler H.T., Notaro R., Araten D.J., Nafa K., Roberts I.A., Weksler M.E., and Luzzatto L. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 96 (2000) 2613-2620
24. Plasilova M., Risitano A.M., O'Keefe C.L., Rodriguez A., Wlodarski M., Young N.S., and Maciejewski J. Shared and individual specificities of immunodominant cytotoxic T-cell clones in paroxysmal nocturnal hemoglobinuria as determined by molecular analysis. Exp Hematol 32 (2004) 261-269
25. Karadimitris A., Li K., Notaro R., Araten D.J., Nafa K., Thertulien R., Ladanyi M., Stevens A.E., Rosenfeld C.S., Roberts I.A., et al. Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. Brit J Haematol 115 (2001) 1010-1014
26. Risitano A.M., Maciejewski J.P., Muranski P., Wlodarski M., O'Keefe C., Sloand E.M., and Young N.S. Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia 19 (2005) 217-222
27. Howe E.C., Wlodarski M., Ball E.J., Rybicki L., and Maciejewski J.P. Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes. Exp Hematol 33 (2005) 1357-1362
28. Poggi A., Negrini S., Zocchi M.R., Massaro A.-M., Garbarino L., Lastraioli S., Gargiulo L., Luzzatto L., and Notaro R. Patients with paroxysmal nocturnal hemoglobinuria have a high frequency of peripheral-blood T cells expressing activating isoforms of inhibiting superfamily receptors. Blood 106 (2005) 2399-2408
29. Terrazzano G., Sica M., Becchimanzi C., Costantini S., Rotoli B., Zappacosta S., Alfinito F., and Ruggiero G. T cells from paroxysmal nocturnal haemoglobinuria (PNH) patients show an altered CD40-dependent pathway. J Leukocyte Biol 78 (2005) 27-36
30. Hanaoka N., Kawaguchi T., Horikawa K., Nagakura S., Mitsuya H., and Nakakuma H. Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP. Blood 107 (2006) 1184-1191
31. Barcellini W., Fermo E., Guia Imperiali F., Zaninoni A., Bianchi P., Boschetti C., and Zanella A. Increased resistance of PIG-A bone marrow progenitors to tumor necrosis factor α and interferon γ: possible implications for the in vivo dominance of paroxysmal nocturnal hemoglobinuria clones. Haematologica 89 (2004) 651-656
32. Takahashi Y., McCoy Jr. J.P., Carvallo C., Rivera C., Igarashi T., Srinivasan R., Young N.S., and Childs R.W. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood 103 (2004) 1383-1390
33. Chen G., Zeng W., Maciejewski J.P., Kcyvanfar K., Billings E.M., and Young N.S. Differential gene expression in hematopoietic progenitors from paroxysmal nocturnal hemoglobinuria patients reveals an apoptosis/immune response in 'normal' phenotype cells. Leukemia 19 (2005) 862-868. Gene expression profiling shows that residual GPI+ cells in the bone marrow of PNH patients are more abnormal than GPI- cells, particularly with respect to pro-apoptotic genes, suggesting that the former cells are being damaged.
34. Zeng W., Miyazato A., Chen G., Kajigaya S., Young N.S., and Maciejewski J.P. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 107 (2006) 167-175
35. Boccuni P., Del Vecchio L., Di Noto R., and Rotoli B. Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. Crc Cr Rev Oncol-Hem 33 (2000) 25-43
36. Ruggiero G., Terrazzano G., Becchimanzi C., Sica M., Andretta C., Masci A.M., Racioppi L., Rotoli B., Zappacosta S., and Alfinito F. GPI-defective monocytes from paroxysmal nocturnal hemoglobinuria patients show impaired in vitro dendritic cell differentiation. J Leukocyte Biol 76 (2004) 634-640
37. Funaro A., Ortolan E., Ferranti B., Gargiulo L., Notaro R., Luzzatto L., and Malavasi F. CD157 is an important mediator of neutrophil adhesion and migration. Blood 104 (2004) 4269-4278. This is the first demonstration that a GPI-linked protein, lacking in PNH neutrophils, is crucial for neutrophil function.
38. Maciejewski J.P., Young N.S., Yu M., Anderson S.M., and Sloand E.M. Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria. Thromb Res 83 (1996) 433-447
39. Grunewald M., Grunewald A., Schmid A., Schopflin C., Schauer S., Griesshammer M., and Koksch M. The platelet function defect of paroxysmal nocturnal haemoglobinuria. Platelets 15 (2004) 145-154
40. Spitzer D., Unsinger J., Bessler M., and Atkinson J.P. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 40 (2004) 911-919
41. Hillmen P., Hall C., Marsh J.C., Elebute M., Bombara M.P., Petro B.E., Cullen M.J., Richards S.J., Rollins S.A., Mojcik C.F., et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New Engl J Med 350 (2004) 552-559. This is the first report of a therapeutic agent that effectively controls intravascular hemolysis in patients with PNH.
42. Hill A., Hillmen P., Richards S.J., Elebute D., Marsh J.C., Chan J., Mojcik C.F., and Rother R.P. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 106 (2005) 2559-2565